Financial results briefings

Financial Highlights for the First Half of the Fiscal Year Ending March 31, 2025

Net sales increased by 1% year on year to 297,079 million yen.
Operating profit was 2,876 million yen, up 0.3 % year on year.
Ordinary profit was 3,637 million yen, up 4.6% year on year.
The interim net profit attributable to owners of parent was 2,420 million yen, up 3.1% year on year.

・Achieved increases in both sales and profits in all the categories. Additionally, the progress made against all of our earnings forecasts exceeded 100%.
・Increase in revenue due to the increased sales of products eligible for the price maintenance premium in the pharmaceutical wholesaling business, our core business.

Fiscal year ending March 2025 (FY2024)

Fiscal year ending March 2024 (FY2023)

Fiscal year ending March 2023 (FY2022)